Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 2, 2010

Bayer Schering Pharma and BRAIN Team Up to Improve Efficiency of Steroid Synthesis

  • Bayer Schering Pharma and BRAIN are pooling their expertise to develop methods for the energy-efficient and sustainable production of steroid compounds by fermentation.

    The goal is to use optimized designer-bug microbial production strains and plant-derived raw materials. The companies hope the new process could enable the achievement of higher yields using lower energy input and potentially reduce greenhouse gas output by some 10%.

    BRAIN is an industrial biotech company specialized in the discovery and development of natural bioactive compounds and enzymes for partners and customers. The company is leveraging its BioArchive, which reportedly comprises millions of genes, proteins, and metabolic pathways from microbial isolates and metagenome libraries.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »